Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3159234 | 0.91 | GAA (0.45) | GSK3BGAAMAPTKMT2ABRD4 | |
| SCHEMBL15673522 | 0.84 | GSK3B (0.45) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL3278108 | 0.83 | GSK3B (0.44) | GSK3BCYP2D6CNR2CYP3A4CYP1A2 | |
| SCHEMBL3280340 | 0.82 | GSK3B (0.42) | GSK3BMAPTKMT2ACYP2D6CNR2 | |
| SCHEMBL3274941 | 0.82 | GSK3B (0.51) | GSK3BMAPTCYP2D6CYP1A2 | |
| SCHEMBL3274431 | 0.82 | NPSR1 (0.44) | GSK3BGAACYP2D6CNR2CYP3A4 | |
| SCHEMBL3275008 | 0.82 | RECQL (0.44) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL3274219 | 0.82 | GSK3B (0.49) | GSK3BGAAMAPTKMT2ACYP2D6 | |
| SCHEMBL3275205 | 0.82 | GSK3B (0.41) | GSK3BMAPTMEN1KMT2ACYP2D6 | |
| SCHEMBL3274046 | 0.80 | NPC1 (0.49) | GSK3BMAPTCYP2D6CNR2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2160387-B1 | HETEROARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI SA (FR) | 2014-05-14 | — | — | EP | claimed |
| US-8592437-B2 | Heteroarylamide pyrimidone compounds | SANOFI (FR) | 2013-11-26 | — | — | US | claimed |
| US-20100087449-A1 | HETEROARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI-AVENTIS (FR) | 2010-04-08 | — | — | US | claimed |
| EP-1992624-A1 | Heteroarylamide pyrimidone compounds | Sanofi-Aventis (FR) | 2008-11-19 | — | — | EP | claimed |
| EP-2160387-B1 | HETEROARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI SA (FR) | 2014-05-14 | — | — | EP | disclosed |
| US-8592437-B2 | Heteroarylamide pyrimidone compounds | SANOFI (FR) | 2013-11-26 | — | — | US | disclosed |
| US-20100087449-A1 | HETEROARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI-AVENTIS (FR) | 2010-04-08 | — | — | US | disclosed |
| EP-2160387-A2 | HETEROARYLAMIDE PYRIMIDONE COMPOUNDS | Sanofi-Aventis (FR) | 2010-03-10 | — | — | EP | disclosed |
| WO-2008155668-A2 | HETEROARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI-AVENTIS (FR) | 2008-12-24 | — | — | WO | disclosed |
| EP-1992624-A1 | Heteroarylamide pyrimidone compounds | Sanofi-Aventis (FR) | 2008-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087449-A1 | HETEROARYLAMIDE PYRIMIDONE COMPOUNDS | DHFR, DPYD, HPRT1 | GSK3B 2561/4885GAA 2327/4885MAPT 3116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.